ReviewInternational journal of nanomedicine2025
Nanomedicine for Acute Kidney Injury: Precision Delivery Strategies, Therapeutic Breakthroughs, Challenges, and Future Perspectives.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Advances and perspectives of functional nanomaterials in scavenging reactive oxygen species for acute kidney injury.Bioactive materials · 2026Review
- Rewiring the mitochondrial NADMaterials today. Bio · 2026Article
- A membrane-fused theranostic nanoplatform for real-time ROS imaging and mitochondrial resuscitation-driven barrier repair in acute kidney injury.Materials today. Bio · 2026Article
- Recent advances in stimuli-responsive nanomaterials for the treatment of acute kidney injury.Journal of nanobiotechnology · 2026Review
- The Role of Non-Coding RNAs in the Pathogenesis and Progression of Diabetic Kidney Disease.International journal of molecular sciences · 2026Review
- Plant metabolites: potential treatments for ischemic acute kidney injury.Frontiers in pharmacology · 2026Review
- Advances in Biomimetic Cell Membrane Nanoplatforms for Renal-Targeted Theranostics: From Pathophysiological Basis to Membrane-Stratified Design.International journal of nanomedicine · 2026Review
- The Current Application Prospects of Nanomedicine in Renal Ischemia-Reperfusion Injury.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a critical condition associated with high mortality rates, currently lacking effective early diagnostic methods and targeted therapeutics. Nanomaterials, due to their unique size effects and modifiability, offer breakthrough strategies for AKI management. This review systematically explores the advancements in the use of nanomaterials for the diagnosis and treatment of AKI: in the diagnostic realm, quantum dot biosensors and ultrasmall contrast agents significantly enhance the sensitivity of early biomarker detection (eg, KIM-1/NGAL); in the therapeutic domain, cerium oxide nanocatalysts (antioxidant), targeted liposomes (anti-inflammatory), and exosome-delivered miRNA (regenerative repair) demonstrate superior renal protection compared to traditional drugs by modulating oxidative stress, inflammation, and apoptosis pathways in animal models. The article emphasizes the design principles of nanomaterials (size <10 nm for renal clearance, cationic surfaces to enhance tubular uptake) and targeting mechanisms. Despite the promising outlook, the clinical translation of nanomaterials faces challenges related to biosafety (long-term retention toxicity) and large-scale production. This review critically evaluates key studies from recent years, providing a theoretical basis and technical roadmap for the development of next-generation nanomedicine platforms for AKI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.